Multi-electrode Radiofrequency Renal Denervation System Feasibility Study
Primary Purpose
Uncontrolled Hypertension
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system
Sponsored by

About this trial
This is an interventional treatment trial for Uncontrolled Hypertension
Eligibility Criteria
Inclusion Criteria:
- Individual is ≥ 18 and ≤ 80 years old.
- Individual has an office systolic blood pressure of 160 mmHG or greater (≥ 150 mmHg for Type 2 diabetics) based on an average of 3 office/clinic blood pressure readings
- Individual is adhering to a stable medication regimen including ≥ 3 anti-hypertensive medications(preferred that one is a diuretic) for a minimum of two weeks prior to screening.
Exclusion Criteria:
- Individual has an estimated glomerular filtration rate (eGFR) of < 45 mL/min/1.73 m2
- Individual has type 1 diabetes mellitus
- Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.
- Individual has primary pulmonary hypertension.
- Individual is pregnant, nursing or planning to be pregnant.
Sites / Locations
- Alfred Hospital
- St. Vincent's Hospital Melbourne
- Epworth Hospital
- Wellington Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Renal Denervation
Arm Description
Outcomes
Primary Outcome Measures
Acute safety as measured by procedural complications
Secondary Outcome Measures
Change in Office Systolic Blood Pressure
Full Information
NCT ID
NCT01699529
First Posted
September 21, 2012
Last Updated
October 24, 2016
Sponsor
Medtronic Vascular
1. Study Identification
Unique Protocol Identification Number
NCT01699529
Brief Title
Multi-electrode Radiofrequency Renal Denervation System Feasibility Study
Official Title
Multi-electrode Radiofrequency Renal Denervation System Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
September 2012 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
October 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medtronic Vascular
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a prospective, single-arm, non-randomized and open label feasibility study. The study is intended to evaluate safety and efficacy of multi-electrode radiofrequency renal denervation in patients with uncontrolled hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uncontrolled Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Renal Denervation
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system
Intervention Description
The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
Primary Outcome Measure Information:
Title
Acute safety as measured by procedural complications
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Change in Office Systolic Blood Pressure
Time Frame
Baseline to 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Individual is ≥ 18 and ≤ 80 years old.
Individual has an office systolic blood pressure of 160 mmHG or greater (≥ 150 mmHg for Type 2 diabetics) based on an average of 3 office/clinic blood pressure readings
Individual is adhering to a stable medication regimen including ≥ 3 anti-hypertensive medications(preferred that one is a diuretic) for a minimum of two weeks prior to screening.
Exclusion Criteria:
Individual has an estimated glomerular filtration rate (eGFR) of < 45 mL/min/1.73 m2
Individual has type 1 diabetes mellitus
Individual requires chronic oxygen support or mechanical ventilation (e.g., tracheostomy, CPAP, BiPAP) other than nocturnal respiratory support for sleep apnea.
Individual has primary pulmonary hypertension.
Individual is pregnant, nursing or planning to be pregnant.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Whitbourn, MD
Organizational Affiliation
St Vincent's Hospital Melbourne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alfred Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3004
Country
Australia
Facility Name
St. Vincent's Hospital Melbourne
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3065
Country
Australia
Facility Name
Epworth Hospital
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3069
Country
Australia
Facility Name
Wellington Hospital
City
Wellington
Country
New Zealand
12. IPD Sharing Statement
Citations:
PubMed Identifier
25982652
Citation
Whitbourn R, Harding SA, Walton A. Symplicity multi-electrode radiofrequency renal denervation system feasibility study. EuroIntervention. 2015 May;11(1):104-9. doi: 10.4244/EIJV11I1A18.
Results Reference
derived
Learn more about this trial
Multi-electrode Radiofrequency Renal Denervation System Feasibility Study
We'll reach out to this number within 24 hrs